AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42
- Registration Number
- NCT00930865
- Locations
- 🇺🇸
Ppd Development, Lp, Austin, Texas, United States
AZD2066 Cocktail Study
Phase 1
Completed
- Conditions
- Chronic Pain
- Interventions
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2009-10-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT00930306
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Study Comparing Gelatine Capsule 40 mg D961H and HPMC Capsule in Japanese Healthy Males
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: D961H
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2009-09-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT00930215
- Locations
- 🇯🇵
Research Site, Fukuoka, Japan
Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) Patients
- First Posted Date
- 2009-06-29
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 329
- Registration Number
- NCT00929708
- Locations
- 🇷🇺
Research Site, St. Petersburg, Russian Federation
ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer
Phase 2
Terminated
- Conditions
- Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy
- Interventions
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00929162
- Locations
- 🇮🇹
Research Site, Roma, Italy
Audit and Screening Study to Determine the Prevalence of Peripheral Arterial Disease
Not Applicable
Completed
- Conditions
- Peripheral Arterial Disease
- Interventions
- Procedure: Ankle-brachial index (ABI) Screening Test
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2009-11-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00928629
- Locations
- 🇦🇺
Research Site, Woodvale, Western Australia, Australia
Epidemiological Study to Evaluate Adherence to Treatment in Bipolar Disorder: Adherence Study
Completed
- Conditions
- Bipolar Disorder
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2009-10-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT00927420
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)
Phase 1
Completed
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: LDAC (low dose cytosine arabinoside)
- First Posted Date
- 2009-06-24
- Last Posted Date
- 2011-06-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4
- Registration Number
- NCT00926731
- Locations
- 🇫🇷
Research Site, Villejuif Cedex, France
Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression
Phase 4
Completed
- Conditions
- Bipolar Depression
- Interventions
- First Posted Date
- 2009-06-23
- Last Posted Date
- 2011-05-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 139
- Registration Number
- NCT00926393
of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).
Completed
- Conditions
- Low Density Lipoprotein Cholesterol Goal Achievement
- First Posted Date
- 2009-06-22
- Last Posted Date
- 2010-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4045
- Registration Number
- NCT00925717
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of